Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated ...
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients ...
Researchers are urging doctors to warn patients about a potential little-known side effect of popular semaglutide drugs that ...
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23 ...
GOTHENBURG, SE / ACCESSWIRE / May 23, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 23, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and ...
GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 22, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering ...
Manufactured by AbbVie, Produodopa is a subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe ...
GOTHENBURG, SE / ACCESSWIRE / May 23, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 23, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and ...
CINCINNATI and HUNTSVILLE, Alabama, May 15, 2024 (GLOBE NEWSWIRE) -- (“Enable”), a healthcare innovation company developing ...
At 28 years old, Dr. Soania Mathur was building her medical practice and expecting her first child. Then she was diagnosed ...
Despite the short half-life of levodopa, in early PD, the symptomatic benefit of levodopa/DDCI appears to last from dose to dose when administered on a three- or four-times daily schedule.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback